Research ArticleArticle
Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs
Robert L. Walsky, R. Scott Obach, Ruth Hyland, Ping Kang, Sue Zhou, Michael West, Kieran F. Geoghegan, Christopher J. Helal, Gregory S. Walker, Theunis C. Goosen and Michael A. Zientek
Drug Metabolism and Disposition September 2012, 40 (9) 1686-1697; DOI: https://doi.org/10.1124/dmd.112.045302
Robert L. Walsky
Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, CT (R.L.W., R.S.O., M.W., K.F.G., C.J.H., G.S.W., T.C.G.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., San Diego, CA (S.Z., P.K., M.A.Z.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Sandwich, United Kingdom (R.H.)
R. Scott Obach
Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, CT (R.L.W., R.S.O., M.W., K.F.G., C.J.H., G.S.W., T.C.G.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., San Diego, CA (S.Z., P.K., M.A.Z.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Sandwich, United Kingdom (R.H.)
Ruth Hyland
Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, CT (R.L.W., R.S.O., M.W., K.F.G., C.J.H., G.S.W., T.C.G.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., San Diego, CA (S.Z., P.K., M.A.Z.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Sandwich, United Kingdom (R.H.)
Ping Kang
Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, CT (R.L.W., R.S.O., M.W., K.F.G., C.J.H., G.S.W., T.C.G.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., San Diego, CA (S.Z., P.K., M.A.Z.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Sandwich, United Kingdom (R.H.)
Sue Zhou
Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, CT (R.L.W., R.S.O., M.W., K.F.G., C.J.H., G.S.W., T.C.G.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., San Diego, CA (S.Z., P.K., M.A.Z.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Sandwich, United Kingdom (R.H.)
Michael West
Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, CT (R.L.W., R.S.O., M.W., K.F.G., C.J.H., G.S.W., T.C.G.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., San Diego, CA (S.Z., P.K., M.A.Z.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Sandwich, United Kingdom (R.H.)
Kieran F. Geoghegan
Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, CT (R.L.W., R.S.O., M.W., K.F.G., C.J.H., G.S.W., T.C.G.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., San Diego, CA (S.Z., P.K., M.A.Z.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Sandwich, United Kingdom (R.H.)
Christopher J. Helal
Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, CT (R.L.W., R.S.O., M.W., K.F.G., C.J.H., G.S.W., T.C.G.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., San Diego, CA (S.Z., P.K., M.A.Z.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Sandwich, United Kingdom (R.H.)
Gregory S. Walker
Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, CT (R.L.W., R.S.O., M.W., K.F.G., C.J.H., G.S.W., T.C.G.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., San Diego, CA (S.Z., P.K., M.A.Z.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Sandwich, United Kingdom (R.H.)
Theunis C. Goosen
Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, CT (R.L.W., R.S.O., M.W., K.F.G., C.J.H., G.S.W., T.C.G.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., San Diego, CA (S.Z., P.K., M.A.Z.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Sandwich, United Kingdom (R.H.)
Michael A. Zientek
Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, CT (R.L.W., R.S.O., M.W., K.F.G., C.J.H., G.S.W., T.C.G.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., San Diego, CA (S.Z., P.K., M.A.Z.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Sandwich, United Kingdom (R.H.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
SELECTIVE INHIBITION OF CYP3A4 BY CYP3cide
Robert L. Walsky, R. Scott Obach, Ruth Hyland, Ping Kang, Sue Zhou, Michael West, Kieran F. Geoghegan, Christopher J. Helal, Gregory S. Walker, Theunis C. Goosen and Michael A. Zientek
Drug Metabolism and Disposition September 1, 2012, 40 (9) 1686-1697; DOI: https://doi.org/10.1124/dmd.112.045302
Research ArticleArticle
SELECTIVE INHIBITION OF CYP3A4 BY CYP3cide
Robert L. Walsky, R. Scott Obach, Ruth Hyland, Ping Kang, Sue Zhou, Michael West, Kieran F. Geoghegan, Christopher J. Helal, Gregory S. Walker, Theunis C. Goosen and Michael A. Zientek
Drug Metabolism and Disposition September 1, 2012, 40 (9) 1686-1697; DOI: https://doi.org/10.1124/dmd.112.045302
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement